No connection

Search Results

SNOA

BEARISH
$2.3 Live
Sonoma Pharmaceuticals, Inc. · NASDAQ
$2.0 52W Range $6.92
Overview AI Snowflake Price Valuation Profitability Growth Health Statements SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 20, 2026
Market cap
$3.98M
P/E
N/A
ROE
N/A
Profit margin
N/A
Debt/Equity
N/A
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
95%
SNOA exhibits critical financial instability, highlighted by a Piotroski F-Score of 0/9, the lowest possible health rating. The company has suffered a catastrophic 98.6% price decline over the last five years and continues to miss earnings estimates consistently (0/4 beats in the last year). While there is a marginal Q/Q revenue increase of 22.03%, it is insufficient to offset persistent losses and a completely bearish technical trend. The lack of an Altman Z-Score and Graham Number further underscores the absence of a stable financial foundation for valuation.

Key Strengths

Recent Q/Q revenue growth of 22.03%
Price-to-Book ratio is relatively low at 1.16
Year-over-year EPS growth is technically positive (+18.6%) despite remaining negative
Maintains current SEC filing compliance (8-K reports)
Low entry price may attract high-risk speculative traders

Key Risks

Critical financial health indicated by a 0/9 Piotroski F-Score
Severe long-term value destruction (-98.6% 5-year change)
Consistent failure to meet earnings expectations with a -30.69% average surprise
Negative forward P/E indicating no path to near-term profitability
Complete lack of analyst coverage and institutional target prices

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
5
Weak
Value
10
Future
15
Past
0
Health
0
Dividend
0
AI Verdict
Critical Risk
Key drivers: Piotroski F-Score 0/9, Catastrophic 5-year price performance, Persistent negative earnings
Confidence
95%
Value
10/100

Traditional valuation metrics are inapplicable due to lack of earnings and missing Graham Number.

Positives
  • P/B ratio of 1.16
Watchpoints
  • Negative Forward P/E
  • No Graham Number available
Future
15/100

Minor revenue growth is overshadowed by a total lack of profitability and bearish momentum.

Positives
  • Q/Q Revenue growth of 22.03%
Watchpoints
  • Bearish technical trend (0/100)
  • Negative EPS progression
Past
0/100

Historical price action represents a near-total loss of capital for long-term holders.

Positives
No standout positives identified.
Watchpoints
  • 5Y Change: -98.6%
  • 3Y Change: -88.3%
Health
0/100

A Piotroski score of 0 indicates the worst possible financial health profile.

Positives
No standout positives identified.
Watchpoints
  • Piotroski F-Score 0/9
Dividend
0/100

Company provides no income return to shareholders.

Positives
No standout positives identified.
Watchpoints
  • No dividend history
  • 0/100 Dividend Strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$2.3

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for SNOA and closest competitors.

Updated 2026-04-17
SNO
Sonoma Pharmaceuticals, Inc.
Primary
5Y
-98.6%
3Y
-88.3%
1Y
0.0%
6M
-40.0%
1M
-6.9%
1W
+0.9%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-4.11
PEG Ratio
N/A
P/B Ratio
1.16
P/S Ratio
N/A
EV/Revenue
N/A
EV/EBITDA
N/A
Market Cap
$3.98M

Profitability

Profit margins and return metrics

Profit Margin N/A
Operating Margin N/A
Gross Margin N/A
ROE N/A
ROA N/A

Growth

Revenue and earnings growth rates

Revenue Growth N/A
Earnings Growth N/A
Q/Q Revenue Growth +22.03%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
N/A
Current Ratio
N/A
Quick Ratio
N/A
Cash/Share
$N/A

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Gross Margin
37.9%
Op. Margin
-15.6%
Net Margin
-18.8%
Total Assets
$0.0B
Liabilities
$0.0B
Equity
$0.0B
Debt/Equity
2.97x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
106%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-02-10
$-0.48
-65.5% surprise
2025-11-04
$-0.32
-3.2% surprise
2025-08-07
$-0.76
-49.0% surprise
2025-02-05
$-0.63
-5.0% surprise

SEC Filings

Recent regulatory filings from the SEC EDGAR database

S-1
FORM S-1
2026-04-17

SNOA filed a Form S-1 on April 17, 2026, to register securities in preparation for an initial public offering.

8-K
CURRENT REPORT
2026-04-09

SNOA filed a current report on April 9, 2026, likely to announce its first-quarter financial results.

10-Q
FORM 10-Q FOR DEC 2025
2026-02-10

SNOA filed its Form 10-Q for the period ending December 2025 on February 10, 2026. While the filing includes a section for risk factors under Item 1A, specific financial highlights and detailed risk disclosures were not provided in the available excerpts.

8-K
CURRENT REPORT
2026-01-28

SNOA filed a current report on January 28, 2026, likely announcing its fourth quarter and full-year financial results.

8-K
FORM 8-K
2026-01-12
8-K
CURRENT REPORT
2026-01-02
10-Q
FORM 10-Q FOR SEP 2025
2025-11-04

SNOA filed its Form 10-Q for the period ending September 2025 on November 4, 2025. While the filing includes a section for risk factors under Item 1A, specific financial highlights and detailed risk disclosures were not provided in the available excerpts.

8-K
FORM 8-K
2025-10-23

SNOA filed a Form 8-K on October 23, 2025, likely to announce its third-quarter financial results.

8-K
CURRENT REPORT
2025-10-09

SNOA filed a current report on October 9, 2025, likely announcing its third-quarter financial results.

8-K
CURRENT REPORT
2025-09-29
8-K
CURRENT REPORT
2025-09-26
8-K
FORM 8-K
2025-08-29
10-Q
FORM 10-Q FOR JUNE 2025
2025-08-07
DEF 14A
DEFINITIVE PROXY STATEMENT
2025-07-11
10-K
FORM 10-K FOR MARCH 2025
2025-06-17
Data sourced from SEC EDGAR. AI summaries generated automatically.

Past News Coverage

Recent headlines mentioning SNOA from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile